{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:55:31Z","timestamp":1793973331950,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jhep.2023.10.041","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T15:57:40Z","timestamp":1699977460000},"page":"322-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Convergent MAPK pathway alterations mediate acquired\u00a0resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-1640","authenticated-orcid":false,"given":"Timothy P.","family":"DiPeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charnel C.","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-7027","authenticated-orcid":false,"given":"Abdel-Baset","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence N.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.10.041_bib1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2023.10.041_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2023.10.041_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.10.041_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jgh.12916","article-title":"Role of the fibroblast growth factor receptor axis in cholangiocarcinoma","volume":"30","author":"Ang","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.041_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib6","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2023.10.041_bib7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2023.10.041_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.10.041_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2023.10.041_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2016.05.017","article-title":"Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein","volume":"380","author":"Wang","year":"2016","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.jhep.2023.10.041_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2023.10.041_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib15","series-title":"Pemazyre (pemigatinib) NDA 213736 approval letter","year":"2020"},{"key":"10.1016\/j.jhep.2023.10.041_bib16","series-title":"Truseltiq (infigratinib) NDA 214622 approval letter","year":"2021"},{"key":"10.1016\/j.jhep.2023.10.041_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2023.10.041_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-021-01100-3","article-title":"FGFR inhibitors: clinical activity and development in the treatment of cholangiocarcinoma","volume":"23","author":"King","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jhep.2023.10.041_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/13543784.2021.1995355","article-title":"Derazantinib: an investigational drug for the treatment of cholangiocarcinoma","volume":"30","author":"Braun","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2023.10.041_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.006","article-title":"LBA12 - efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Hollebecque","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what's now and what's next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2023.10.041_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhep.2023.10.041_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/1535-7163.MCT-17-0367","article-title":"Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3beta","volume":"17","author":"Lau","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2023.10.041_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2023.10.041_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to\u00a0ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2023.10.041_bib27","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2019.37.15_suppl.4096","article-title":"Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"37","author":"Varghese","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2023.10.041_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jhep.2023.10.041_bib31","series-title":"Adapted from \"PI3K\/Akt, RAS\/MAPK, JAK\/STAT signaling","year":"2022"},{"issue":"7","key":"10.1016\/j.jhep.2023.10.041_bib32","doi-asserted-by":"crossref","first-page":"djv098","DOI":"10.1093\/jnci\/djv098","article-title":"A decision support framework for genomically informed investigational cancer therapy","volume":"107","author":"Meric-Bernstam","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2023.10.041_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00036","article-title":"Clinical use of precision oncology decision support","author":"Johnson","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2023.10.041_bib34","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/cas.15378","article-title":"Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma","volume":"113","author":"Iseda","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2023.10.041_bib35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41416-022-01878-4","article-title":"The novel FGFR inhibitor F1-7 induces DNA damage and cell death in colon cells","volume":"127","author":"Liu","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2023.10.041_bib36","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.041_bib37","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2023.10.041_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","article-title":"FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma","volume":"75","author":"Cristinziano","year":"2021","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:12:51Z","timestamp":1739553171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823052741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0168827823052741"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.041","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convergent MAPK pathway alterations mediate acquired\u00a0resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}